Athira Pharma, Inc.
ATHA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $16,328 | $11,806 | $11,127 | $22,588 |
| - Cash | $20,874 | $19,888 | $26,422 | $48,438 |
| + Debt | $912 | $1,017 | $1,117 | $1,217 |
| Enterprise Value | -$3,634 | -$7,065 | -$14,178 | -$24,633 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$243 | -$200 | -$243 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$6,503 | -$6,766 | -$8,900 | -$15,323 |
| % Margin | – | – | – | – |
| Net Income | -$6,611 | -$6,966 | -$9,143 | -$15,003 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.68 | -1.78 | -2.3 | -3.9 |
| % Growth | 5.6% | 22.6% | 41% | – |
| Operating Cash Flow | -$4,668 | -$6,999 | -$14,665 | -$26,013 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$4,668 | -$6,999 | -$14,665 | -$26,013 |